<DOC>
	<DOCNO>NCT02199691</DOCNO>
	<brief_summary>The purpose trial evaluate immunogenicity safety MenACYW conjugate vaccine compare licensed product , MENVEO vaccine also evaluate MenACYW conjugate vaccine give alone compare give Tdap vaccine HPV vaccine . Primary objective : - To evaluate antibody response antigens present MenACYW conjugate vaccine MenACYW conjugate vaccine give alone compare MENVEO vaccine give alone . Secondary objective : - To evaluate antibody response antigens present MenACYW conjugate vaccine , MenACYW conjugate vaccine give concomitantly Tdap HPV vaccine , compare give alone - To evaluate antibody response antigens present Tdap vaccine , Tdap vaccine give concomitantly MenACYW conjugate vaccine HPV vaccine , compare Tdap vaccine give HPV vaccine Observational objective : - To describe safety profile MenACYW conjugate vaccine , compare licensed vaccine MENVEO® , MenACYW conjugate vaccine give Tdap HPV vaccine .</brief_summary>
	<brief_title>Immunogenicity Safety Investigational Quadrivalent Meningococcal Conjugate Vaccine Healthy Adolescents</brief_title>
	<detailed_description>Participants receive assign vaccine evaluate immunogenicity safety . The duration participation trial approximately 180 210 day .</detailed_description>
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Meningitis , Meningococcal</mesh_term>
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Aged 10 17 year day inclusion Informed consent form sign dated parent ( ) another legally acceptable representative Assent form sign date subject Subject parent legally acceptable representative able attend schedule visit comply trial procedure . Subject pregnant , lactating , childbearing potential ( consider nonchildbearing potential , female must premenarche , surgically sterile , use effective method contraception abstinence least 4 week prior first vaccination least 4 week last vaccination ) Participation 4 week precede first trial vaccination ( ) plan participation present trial period another clinical trial investigate vaccine , drug , medical device , medical procedure Receipt vaccine 4 week precede first trial vaccination ( ) plan receipt vaccine 4 week prior follow trial vaccination except influenza vaccination , may receive least 2 week study vaccine . This exception include monovalent influenza vaccine multivalent influenza vaccine . Previous vaccination meningococcal disease either trial vaccine mono polyvalent polysaccharide conjugate meningococcal vaccine contain A , C , W , Y antigens History vaccination tetanus , diphtheria , pertussis vaccine within previous 4 year Previous HPV vaccination Receipt immune globulin , blood bloodderived product past 3 month Known suspected congenital acquire immunodeficiency ; receipt immunosuppressive therapy , anticancer chemotherapy radiation therapy , within precede 6 month ; longterm systemic corticosteroid therapy ( prednisone equivalent 2 consecutive week within past 3 month ) History meningococcal infection , confirm either clinically , serologically , microbiologically At high risk meningococcal infection trial ( i.e. , subject persistent complement deficiency , anatomic functional asplenia , subject travel country high endemic epidemic disease ) Known systemic hypersensitivity vaccine component , history lifethreatening reaction vaccine use trial vaccine contain substance , include encephalopathy ( e.g. , coma , decrease level consciousness , prolonged seizure ) within 7 day administration previous pertussis antigencontaining vaccine Personal history GuillainBarré syndrome Personal history Arthuslike reaction vaccination tetanus toxoidcontaining vaccine within least 10 year propose study vaccination Verbal report thrombocytopenia , contraindicate intramuscular vaccination Bleeding disorder , receipt anticoagulant 3 week precede inclusion , contraindicate intramuscular vaccination Deprived freedom administrative court order , emergency setting , hospitalize involuntarily Current alcohol abuse drug addiction Chronic illness ( e.g. , HIV hepatitis B , hepatitis C ) , opinion investigator , stage might interfere trial conduct completion Moderate severe acute illness/infection ( accord investigator judgment ) day vaccination febrile illness ( temperature ≥ 100.4°F ) . A prospective subject include study condition resolve febrile event subside Receipt oral injectable antibiotic therapy within 72 hour prior first blood draw Identified Investigator employee Investigator study center direct involvement propose study , identify immediate family member ( i.e. , natural adopt child ) Investigator employee direct involvement propose study .</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Meningitis</keyword>
	<keyword>Meningococcal Meningitis</keyword>
	<keyword>MenACYW conjugate vaccine</keyword>
	<keyword>MENVEO vaccine</keyword>
	<keyword>Adacel®</keyword>
	<keyword>GARDASIL®</keyword>
</DOC>